Contact Us

Biovica Capital Markets Day invitation June 9

2021-05-22 14:30

Biovica, active in cancer diagnostics, will host a virtual Capital Markets Day on Wednesday 9 June from 14.00 to 16.30.

Biovica is approaching market launch of DiviTum®TKa in the US for the monitoring of metastatic breast cancer treatments. Today, DiviTum®TKa is sold for research purposes primarily to major pharmaceutical companies for use in clinical studies. Following FDA approval expected in 2021, the large market for patient monitoring will be available.

We therefore invite you to a virtual Capital Markets Day on June 9, 2021 at 14.00 to 16.30.
https://tv.streamfabriken.com/biovica-international-virtual-capital-markets-day-2021

Questions can be sent in advance or during the event to ir@biovica.com

At the Capital Markets Day, among others, Luca Malorni, MD, PhD, will participate to give his view on DiviTum®TKa. Dr. Malorni is a medical oncologist and Director of the Translational Research Unit of the Hospital of Prato and principal investigator in several studies with DiviTum®TKa.

Welcome!

Contact

Anders Rylander, CEO
Phone: +46-18-444 48 35
E-mail: anders.rylander@biovica.com

Biovica – Treatment decisions with greater confidence

Biovica develops and commercializes blood-based biomarker assays to evaluate efficacy of cancer treatments. Biovica’s assay DiviTum® measure cell proliferation by detecting a biomarker in the blood stream. The assay has successfully demonstrated its capabilities to early evaluate therapy effectiveness in several clinical trials. The first application for DiviTum is monitoring of treatment for patients with metastatic breast cancer. Biovica's vision is that all cancer patients will get an optimal treatment from day one. Biovica collaborates with world-leading cancer institutes and pharmaceutical companies. DiviTum is CE-marked and registered with the Swedish Medical Products Agency. Biovica's shares are traded on the Nasdaq First North Growth Market (BIOVIC B). FNCA Sweden AB is the company's Certified Adviser, info@fnca.se, +46 8 528 00 399. For more information please visit: www.biovica.com.

This information is information that Biovica International is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2021-05-22 14:30 CEST.

Attachments

Biovica Capital Markets Day invitation June 9

>4,500

Numbers of patients in studies

28

Publications

19

Pharma Projects

Are you a US resident?

Only US residents will be able to qualify for this program

No